SI-BONE, Inc. Stock News

FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone

Delivered ~15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physician base

Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board Member Appointments build the financial and governance fou...

Gazprom Neft , ​the oil arm ‌of Russia's energy giant ​Gazprom , ​said on Friday its ⁠first-quarter ​net profit declined ​by 3.5% year-on-year to 95.8 ​billion roubles ($1.35 ​billion).

SiBone NASDAQ: SIBN raised its full-year 2026 outlook after reporting double-digit revenue growth in the first quarter, with management pointing to new product launches, expanding physician adoption, international momentum and a proposed Medicare reimbursement change as key drivers for the year ahead.

Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA

SANTA CLARA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 BofA Securities Healthcare Conference in Las Vegas, NV. Management will be hosting a fireside chat on Tuesday, May 12...